ロード中...
A Phase 1b Study of Vismodegib with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
INTRODUCTION: Components of the hedgehog signaling pathway are upregulated in patients with idiopathic pulmonary fibrosis (IPF). Vismodegib, a small-molecule inhibitor of hedgehog signaling, when used in combination with currently available antifibrotic therapy, may be more efficacious than antifibr...
保存先:
| 出版年: | Pulm Ther |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Springer Healthcare
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6967289/ https://ncbi.nlm.nih.gov/pubmed/32026407 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s41030-019-0096-8 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|